Employers get one platform for GLP-1 access, hormone therapy and chronic disease coaching, with clinicians still signing off ...

SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington.

A new review argues that aging has several brakes, not one, and that the way genes are switched may hit the limit first.

Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.

A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...

Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – but lipids unmoved. Professor Christian Heiss and his University of Surrey ...

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

Fractyl Health’s Revita beat a sham procedure on its six-month goal in a pivotal trial, but the FDA’s 12-month bar is the ...

Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.

RoC is recruiting at least 30 pairs of women 40 and older for a 12-week study that pairs skin checks with sleep and stress data.